Charles River Laboratories Intl. Inc vs iShares International Treasury Bond ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while iShares International Treasury Bond ETF trades at $39.74 (market cap $1.30B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 10.9× iShares International Treasury Bond ETF's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and iShares International Treasury Bond ETF for 92 Days on average.
| CRL | IGOV | |
|---|---|---|
Market Cap | $14.23B | $1.30B |
Volume | 1,176,885 | 693,740 |
Sector | Health | Fixed Income |
52-Week High | $310.77 | $42.99 |
52-Week Low | $149.93 | $39.65 |
Typical Hold Time | 33 Days | 92 Days |
Enterprise Value | $17.06B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
IGOV trades at $39.73, up 0.08% on the day, with a bearish technical signal from moving averages but neutral oscillators. Key financial ratios such as P/E and P/S are not available in the provided data. Recent news highlights rising global bond yields, which may impact interest-rate-sensitive assets.
The outlook remains cautious due to bearish technicals and macroeconomic pressures from higher yields. Investment opportunities hinge on undisclosed fundamentals, while risks include market volatility and interest rate sensitivity. Investors should await clearer financial disclosures for a full assessment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →